Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 12/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509662 | 1.00 | DPP4 (0.49) | DPP4DPP8DPP9XIAPPOLB | |
| SCHEMBL1509596 | 0.90 | XIAP (0.57) | DPP4DPP8DPP9XIAPPOLB | |
| SCHEMBL31072116 | 0.86 | XIAP (0.49) | DPP4XIAPPOLBELANE | |
| SCHEMBL29689606 | 0.83 | XIAP (0.53) | DPP4DPP8DPP9XIAPPOLB | |
| SCHEMBL31072121 | 0.82 | XIAP (0.46) | DPP4XIAPPOLBELANE | |
| SCHEMBL1509704 | 0.82 | XIAP (0.48) | DPP4DPP8DPP9XIAPPOLB | |
| SCHEMBL1509677 | 0.79 | DPP4 (0.54) | DPP4DPP8DPP9POLBDPP7 | |
| SCHEMBL20781245 | 0.78 | POLB (0.63) | XIAPPOLBELANE | |
| SCHEMBL20754239 | 0.78 | POLB (0.63) | XIAPPOLBELANE | |
| SCHEMBL22127783 | 0.78 | POLB (0.63) | XIAPPOLBELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | claimed |
| US-8470781-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2013-06-25 | — | — | US | claimed |
| EP-1675578-B1 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2013-05-22 | — | — | EP | claimed |
| EP-2289498-A1 | Use of inhibitors of glutaminyl clyclase | Probiodrug AG (DE) | 2011-03-02 | — | — | EP | claimed |
| EP-1620082-B9 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-08-25 | — | — | EP | claimed |
| EP-2206496-A1 | Medical use of inhibitors of glutaminyl and glutamate cyclases | Probiodrug AG (DE) | 2010-07-14 | — | — | EP | claimed |
| EP-1620082-B1 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR TREATING ALZHEIMER'S DISEASE AND DOWN SYNDROME | PROBIODRUG AG (DE) | 2010-04-21 | — | — | EP | claimed |
| US-20090149394-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2009-06-11 | — | — | US | claimed |
| US-7462599-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2008-12-09 | — | — | US | claimed |
| EP-1961416-A1 | Medical use of inhibitors of glutaminyl and glutamate cyclases | Probiodrug AG (DE) | 2008-08-27 | — | — | EP | claimed |
| US-7381537-B2 | Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease | PROBIODRUG AG (DE) | 2008-06-03 | — | — | US | claimed |
| US-20060189523-A1 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2006-08-24 | — | — | US | claimed |
| US-20030135023-A1 | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis | PROSIDION LIMITED (GB) | 2003-07-17 | — | — | US | claimed |
| US-8470781-B2 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-1961416-B1 | Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis. | PROBIODRUG AG (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-6890905-B2 | Methods for improving islet signaling in diabetes mellitus and for its prevention | PROSIDION LIMITED (GB) | 2005-05-10 | — | — | US | disclosed |
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | PROBIODRUG AG (DE) | 2005-03-17 | — | — | US | disclosed |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20030135023-A1 | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis | PROSIDION LIMITED (GB) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135023-A1 | Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis | PEPD, DNPEP, ANPEP | DPP4 4/4885DPP8 21/4885DPP9 7/4885 |
| US-20060189523-A1 | Use of effectors of glutaminyl and glutamate cyclases | GLS, GLUL, GLS2 | DPP4 1981/4885DPP8 3636/4885DPP9 2668/4885 |
| US-20090149394-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | GLS, GLUL, GLS2 | DPP4 1981/4885DPP8 3636/4885DPP9 2668/4885 |
| US-20040224875-A1 | Inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | DPP4 2056/4885DPP8 2739/4885DPP9 1376/4885 |
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | GLS, QPCT, GLS2 | DPP4 564/4885DPP8 1336/4885DPP9 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.